Stryker Corporation (SYK)

FairStock Score: 50/100 — MIXED

Key Financials

Strengths

• Strong free cash flow generation of $4.2B demonstrates underlying business quality
• Defensive healthcare sector with recurring revenue and low business cycle sensitivity (beta 0.87)
• Solid Piotroski F-Score of 7/9 indicates improving operational fundamentals
• Market leadership in medical devices across multiple segments with high barriers to entry
• Altman Z-Score of 4.29 indicates excellent financial stability and no bankruptcy risk

Concerns

• Valuation is egregiously stretched at P/E of 40 with Graham Number of only $53.99 (margin of safety: -564%)
• EV/EBITDA of 68.11 is unsustainable and leaves no room for error or business interruption
• Weak FCF yield of 1.4% provides minimal return on capital at current price levels
• ROCE of 7.92% is inadequate relative to the company's cost of capital, indicating value destruction

AI Analysis

I'm examining Stryker with considerable skepticism. Here's a company trading at $358.65 with a P/E of 40 and a Graham Number of just $53.99—suggesting it's priced at nearly 7 times what conservative analysis would justify. The margin of safety is deeply negative at -564%, which alone disqualifies this from our circle of competence. That said, Stryker possesses genuine business quality. With $4.2B in free cash flow, a respectable ROE of 15.08%, and a Piotroski F-Score of 7/9, the underlying business demonstrates operational competence. The company operates in defensive healthcare with recurring revenue from medical devices across surgical equipment, orthopedics, and neurotechnology. The low beta of 0.87 suggests stability. However, the valuation is where I must draw a firm line. An EV/EBITDA of 68.11 is absurdly stretched. The FCF yield of just 1.4% provides minimal margin for error. A D/E ratio of 0.73 is manageable, but the balance sheet doesn't justify this premium. The FairStock Score of 38/100 confirms my analysis. Stryker is a quality compounder in a growing industry—medical devices benefit from aging demographics and technological advancement. But quality alone doesn't justify price. I've learned that even wonderful companies become poor investments at wonderful prices. At current levels, I'd pass. If this stock corrected to $150-180, where the Graham Number might suggest fair value, I'd reassess. For now, it's a lesson in discipline: never confuse business quality with investment opportunity.

Bull Case

Stryker operates in a secular growth industry benefiting from aging populations and technological advancement in surgical innovation. With 56,000 employees globally and a diversified product portfolio, the company has strong competitive moats and should compound earnings at mid-single to high-single-digit rates for years.

Bear Case

The valuation represents peak enthusiasm for medical device companies. If growth disappoints, if operating margins compress due to competition or regulatory pressure, or if healthcare spending slows, investors could face significant multiple compression on top of poor absolute returns at 1.4% FCF yield.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer